In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, ...
(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...
GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs ...
On October 15, 2024, GSK filed two complaints against Moderna in the District Court for the District of Delaware, asserting that Moderna willfully infringes GSK’s mRNA patent portfolio. In Civil ...
GlaxoSmithKline Pharmaceuticals reported a notable 16% rise in consolidated net profit for the September quarter, reaching Rs 252 crore. This growth was driven by robust sales and brand performance.
Other Operating Income------Total Income From Operations: 1,010.77: 814.65: 956.99: EXPENDITURE ...
India's GlaxoSmithKline Pharmaceuticals reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and vaccines.
Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback